HGSOC patients with BRCA1/2 mutations show HRD and PARPi sensitivity. Notably, HRD and PARPi response can occur without BRCA mutations, suggesting other factors are involved. Loss of CCDC6 function can lead to HRD and PARPi sensitivity in HGSOC cells, making CCDC6 a potential therapeutic target and biomarker. Three CCDC6 missense mutations in HGSOC prompted investigation into their impact on HRD. Analyzing CCDC6 expression, localization and HRD data in the MITO16A trial aims to clarify the CCDC6-HRD relationship in a large cohort. The biochemical and morphological effects of CCDC6 mutants on the native protein were examined using pull-down assays and immunofluorescence. HR-reporter and cell viability assays determined the impact of these mutants on HRD and PARPi sensitivity. CCDC6 histochemical score and intracellular-localization were assessed in MITO16A samples after immunostaining and digitalization. CCDC6-mutated isoforms act as dominant-negative, preventing native CCDC6 nuclear translocation, disrupting RAD51 foci and HR-repair, and increasing PARPi sensitivity. In the MITO16A patient sample set, 66 of 185 (35%) showed barely detectable CCDC6 or nuclear exclusion ("CCDC6-inactive"). CCDC6 impairment in these "CCDC6-inactive" samples was associated with HRD in 75% (30/40) of suitable samples analyzed by the RAD51 test and in 52% (34/65) of suitable samples analyzed by genomic HRD testing, even in the presence of wild-type BRCA1/BRCA2 genes. The association between CCDC6 inactivity and HRD, both at genomic and functional level, occurred even in presence of wild-type BRCA1/BRCA2 genes, suggesting that CCDC6 may play a crucial role in DNA repair pathways independent of these well-known genes.
(1) Background: Cancer is a leading cause of death worldwide and each year, approximately 400,000 children develop cancer. Early detection of cancer greatly increases the chances for successful treatment, while screening aims to identify individuals with findings suggestive of specific cancer or pre-cancer before they have developed symptoms. Precise detection, however, often mainly relies on human experience and this could suffer from human error and error with a visual inspection. (2) Methods: The research of statistical approaches to analyze the complex structure of data is increasing. In this work, an entropy-based fuzzy clustering technique for interval-valued data (EFC-ID) for cancer detection is suggested. (3) Results: The application on the Breast dataset shows that EFC-ID performs better than the conventional FKM in terms of AUC value (EFC-ID = 0.96, FKM = 0.88), sensitivity (EFC-ID = 0.90, FKM = 0.64), and specificity (EFC-ID = 0.93, FKM = 0.92). Furthermore, the application on the Multiple Myeloma data shows that EFC-ID performs better than the conventional FKM in terms of Chi-squared (EFC-ID = 91.64, FKM = 88.26), Accuracy rate (EFC-ID = 0.71, FKM = 0.60), and Adjusted Rand Index (EFC-ID = 0.33, FKM = 0.21). (4) Conclusions: In all cases, the proposed approach has shown good performance in identifying the natural partition and the advantages of the use of EFC-ID have been detailed illustrated.
CCDC6 inactivation reduces RAD51 foci formation in HGSOC cells. A and B, Representative immunofluorescence images and quantitative analysis of RAD51 foci formation in OVCAR3 (A) and OV90 (B) cells transfected with the myc-tagged CCDC6 WT; the mutated isoforms A226S, L217P, and P442S expression vectors; or the EV as a control, following treatment with etoposide (10 μmol/L) for 8 hours. Graphs represent the percentage of cells with more than five foci. Error bars indicate the SEM derived from three independent experiments. Statistical significance was verified by one-way ANOVA (****, P < 0.0001). C and D, Representative immunofluorescence images and quantitative analysis of RAD51 foci formation in OVCAR3 (C) and OV90 (D) cells stably silenced for CCDC6 (shCCDC6) and transfected with the myc-tagged CCDC6 WT; the mutated isoforms A226S, L217P, and P442S expression vectors; or the EV and control cells (shCTRL), following treatment with etoposide (10 μmol/L) for 8 hours. Graphs represent the percentage of cells with more than five foci. Error bars indicate the SEM derived from three independent experiments. Statistical significance was verified by one-way ANOVA (****, P < 0.0001).
Patients with high-grade serous ovarian carcinoma (HGSOC) with BRCA1/2 mutations show homologous recombination (HR) deficiency (HRD) and poly (ADP-ribose) polymerase inhibitors (PARPi) sensitivity. Notably, HRD and PARPi response can occur without BRCA mutations, suggesting that other factors are involved. Loss of coiled-coil domain containing 6 (CCDC6) function can lead to HRD and PARPi sensitivity in HGSOC cells, making CCDC6 a potential therapeutic target and biomarker. Three CCDC6 missense mutations in HGSOC prompted an investigation into their impact on HRD. Analyzing CCDC6 expression, localization, and HRD data in the MITO16A trial aims to clarify the CCDC6–HRD relationship in a large cohort. The biochemical and morphologic effects of CCDC6 mutants on the native protein were examined using pull-down assays and immunofluorescence. HR-reporter and cell viability assays determined the impact of these mutants on HRD and PARPi sensitivity. The CCDC6 histochemical score and intracellular localization were assessed in MITO16A samples after immunostaining and digitalization. CCDC6-mutated isoforms act as dominant-negative, preventing native CCDC6 nuclear translocation, disrupting RAD51 foci and HR repair, and increasing PARPi sensitivity. In the MITO16A patient sample set, 66 of 185 (35%) showed barely detectable CCDC6 or nuclear exclusion (“CCDC6-inactive”). CCDC6 impairment in these “CCDC6-inactive” samples was associated with HRD in 75% (30/40) of suitable samples analyzed by the RAD51 test and in 52% (34/65) of suitable samples analyzed by genomic HRD testing, even in the presence of wild-type (WT) BRCA1/BRCA2 genes. The association between CCDC6 inactivity and HRD, both at the genomic and functional levels, occurred even in the presence of WT BRCA1/BRCA2 genes, suggesting that CCDC6 may play a crucial role in DNA repair pathways independent of these well-known genes.Significance:In ovarian cancer, inactivation of the CCDC6 protein signals a defect in DNA repair, known as HRD. This finding might expand the pool of patients, including those who are BRCA WT, who can receive PARP inhibitors, significantly broadening access to this targeted, life-extending therapy.
CCDC6 inactivation correlates with an HRD phenotype in patients with HGSOC. A, Representative images of IHC analysis of CCDC6 expression (a–c) and localization (d–f) in FFPE MITO16A patient samples (magnification 40×). The H-score values are listed as follows: a, (9); b, (50.68); c, (138.86); d, (149.61); e, (194.51); and f, (262.82). B, Summary of the MITO16A cases with CCDC6 inactivation, assessed for HRD test and/or RAD51 test and/or BRCA1/2 status. C, Causes of failure for the RAD51 assay in CCDC6 inactive samples. D, Percentages of Homologous Recombination Proficiency (HRP) and HRD tumors assessed by functional HRD testing among CCDC6 inactive MITO16A samples. E, Percentages of non-HRD and HRD tumors assessed by genomic HRD testing among CCDC6 inactive MITO16A samples. F, Percentage of BRCA1 and BRCA2 WT or mutated tumors among CCDC6-inactive MITO16A samples.